Physiological mapping and prediction reveal stress-responsive translation initiation landscapes

Ichihara, K.; Shiraishi, T.; Morita, H.; Shiraishi, C.; Hirata, M.; Yamashiki, N.; Setsu, S.; Tsuboyama, K.; Hatano, A.; Tokita, S.; Mishiro-Sato, E.; Sakamoto, A.; Ito, T.; Abe, K.; Seki, M.; Suzuki, Y.; Ajiro, M.; Yoshimi, A.; Kanaseki, T.; Matsumoto, M.; Adachi, S.; Baranov, P. V.; Shimamura, T.; Matsumoto, A.

doi:10.64898/2026.11.03.763266

Home/Archive/bioRxiv

bioRxiv · 10.64898/2026.11.03.763266

Physiological mapping and prediction reveal stress-responsive translation initiation landscapes

View original source ↗Export metadata ↓

Abstract

Translation initiation defines the protein output of the transcriptome, but its physiological dynamics in cells and tissues remain incompletely characterized. Here we develop TISCA2, an inhibitor-free method that captures eIF5B-associated initiating ribosomes to map translation initiation sites genome-wide. By directly identifying start sites rather than inferring translation from elongating-ribosome periodicity, TISCA2 improves the detection of short and overlapping translons. Translation of a subset of TISCA2-identified translons is supported by N-terminal proteomics and HLA-I immunopeptidomics. The arsenite-induced integrated stress response broadly redistributes start-site usage, reducing upstream initiation in favor of downstream initiation. TISCA2 further reveals tissue-specific initiation landscapes in vivo, with increased detection of downstream candidate start sites in the testis. Finally, we develop IncepTIS, a sequence-based deep learning model that predicts position-resolved and condition-dependent initiation landscapes. IncepTIS-guided optimization generates de novo mRNA 5' leaders with stress-responsive initiation patterns. Together, TISCA2 and IncepTIS provide an experimental and computational framework for mapping, predicting and engineering translation initiation in mammalian cells and tissues.

Explore related subjects

molecular biology Preprint

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

Ichihara, K., Shiraishi, T., Morita, H., Shiraishi, C., Hirata, M., Yamashiki, N., Setsu, S., Tsuboyama, K., Hatano, A., Tokita, S., Mishiro-Sato, E., Sakamoto, A., Ito, T., Abe, K., Seki, M., Suzuki, Y., Ajiro, M., Yoshimi, A., Kanaseki, T., Matsumoto, M., Adachi, S., Baranov, P. V., Shimamura, T., Matsumoto, A.. 2026-11-05. Physiological mapping and prediction reveal stress-responsive translation initiation landscapes. https://doi.org/10.64898/2026.11.03.763266

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

bioRxiv2026

Optimal compositions of potent sliced-siRNA with DNA bases substitution and insights of Ago2 slicing actions

We have previously characterized the nucleotide compositions of single-stranded ago2-sliced small interfering RNAs (sliced-siRNA, sliRNA), a novel type of potent RNAi trigger designed based on the biogenesis mechanism of miRNA-451. sliRNAs have on par antisense mediated silencing activity but about 1000-fold reduced passenger strand activity compared to siRNA. In the current study, to further characterize sliRNAs to facilitate their in vivo application, we have investigated the effects of substituting RNA nucleotides (nts) in sliRNA with DNA nts (sliDRNAs), which will allow us to study the potential effects on their processing, maturation, and silencing activity from individual or multiple nts at different positions. Our results showed sliDRNAs have distinguished composition from siRNA with DNA nts (siDRNA), indicated that, in addition to their different biogenesis mechanisms, these two types of RNAi triggers may also have adopted additional different silencing mechanisms. Our results also revealed some mechanism related to how Ago2 executes its slicer activity and the effects on sliRNA potency by trimming and tailing during sliRNA maturation. These results have paved the way for using other chemically modified nts in sliRNAs that may enhance their in vivo stability and transportability to facilitate their in vivo applications.

molecular biology↗

bioRxiv2026

Hijacking Cellular S-Acylation with Molecular Assemblies Rewires Oncogenic Signaling

KRAS-mutant cancers are generally treated by suppressing oncogenic signaling. Here, we investigated whether endogenous lipidation machinery could instead be used to spatially perturb that signaling. The thioester-bearing peptide precursor Stb-DPhe-DPhe-SAc (1) potently reduced PANC-1 cell viability and formed a palmitoylated product in treated cells. Synthetic palmitoylated 1 displayed increased assembly propensity, while fluorescent analogue 2 accumulated at the Golgi in a 2-bromopalmitate-sensitive manner. Compound 1 increased plasma-membrane-associated KRAS staining and ERK/AKT phosphorylation and induced pronounced LC3B and p62 remodeling. Inhibition of palmitoylation suppressed Golgi accumulation, attenuated the LC3B response, and rescued cell viability. These findings support a model in which cellular S-acylation drives organelle-localized molecular assembly that perturbs KRAS localization, oncogenic signaling, and associated stress responses. This work identifies endogenous lipidation machinery as a synthetic handle for spatial control of cancer signaling.

molecular biology↗

bioRxiv2026

Metformin lowers HMGA1a and RBM3 protein in breast cancer cells, and its effect on ESR1 splicing depends on cell density and exposure time

The ESR1 gene produces ER46, an N-terminally truncated isoform generated by skipping of exon 1, which is reduced in tamoxifen-resistant breast cancer cells. We have reported that metformin moves the ratio of full-length ER to ER46 in opposite directions in MCF-7 cells and their tamoxifen-resistant subline TAMR1, and that metformin reduces TAMR1 xenograft growth (Harada et al., Am J Pharm Health Res 2022;10(11)). That report leaves two questions open: whether the effect is dosedependent and stable across culture conditions, and what splicing factor might carry it. Here we report the experiments that bear on both. Across a full dose range from 0.25 to 5 mM at high seeding density, metformin produced no consistent change in the full-length share of ESR1 transcript in either line: densitometry of the gel gave 42%, 43%, 42%, 43%, 45% and 48% in MCF-7 cells and 55%, 44%, 52%, 47%, 68% and 43% in TAMR1 cells. The reported shift therefore depends on the seeding density used, and the comparison that produced it is not reproduced at high density. At low density the MCF-7 response persisted to 48 h (52%, 62% and 68% at 0, 2.5 and 5 mM). Metformin lowered HMGA1a protein in MCF-7 cells and showed the same tendency in TAMR1 cells, at both seeding densities, and lowered RBM3 protein in TAMR1 cells at 24 and 48 h. HMGA1a is the factor we previously showed to generate ER46 by trapping U1 snRNP at an upstream pseudo-5' splice site, so a fall in HMGA1a predicts less ER46, the opposite of what was seen in TAMR1 cells at low density. The fall in RBM3, the protein through which metformin alters splicing in myotonic dystrophy, is the more plausible candidate. RT-PCR of the xenograft tumours from the earlier study detected full-length ESR1 transcript in the untreated and tamoxifen-plus-metformin groups but not in the singleagent groups, with amplification failing in several lanes; these panels do not separate the treatments. Taken together, the direction of the metformin effect on ESR1 splicing is conditional on culture density and does not survive a dose-response test at high density, and HMGA1a is unlikely to be the factor that carries it.

molecular biology↗